FIGURE 4.

Ganetespib increased inhibition of tumor growth mediated by ibrutinib in the mouse model. (A). The scheme of in vivo experimental settings. Mice bearing Jeko-1 xenografts (n = 6/group) were randomly grouped into four groups and treated with 15 mg/kg ganetespib (or vehicle) once weekly by i.v. and 50 mg/kg ibrutinib (or vehicle) daily by i.p. over a period of 10 days. (B). Ganetespib significantly increased inhibition of tumor growth mediated by ibrutinib. Data show the average growth of tumor volumes calculated at the indicated days and the error bars are the S.D. (C). The picture of the tumors at the day of sacrifice. (D). Ganetespib significantly increased inhibition of tumor growth mediated by ibrutinib. Data show the average tumor weight and the error bars are the S.D. (n = 6/group). Differences among groups were compared by the Mann–Whitney test, with p < 0.05 considered significant (*p < 0.05; **p < 0.01). (E,F) Representative images of IHC staining and statistics of the expression of Ki-67 and BCL-2 in the tumors after treatment (scale bar = 50 μm). Mean ± SD, n = 3.